07:53 AM EDT, 07/22/2024 (MT Newswires) -- Zymeworks ( ZYME ) said on Monday that the Food and Drug Administration has cleared the investigational new drug application for its experimental cancer therapy, ZW191.

The company said it plans to seek regulatory approval to start clinical trials for ZW191 in countries outside the US by H2 2024.

ZW191 is the first of three ADC molecules using the company's proprietary ZD06519 payload designated for clinical development, with investigational new drug application filings for ZW220 and ZW251 expected to follow in 2025, Zymeworks ( ZYME ) said.

Price: 9.59, Change: -0.19, Percent Change: -1.94